Patient P-01736
Therapy response
Stable
Tolerance
Stable
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
90%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S03
- Day 49 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 62 ME-01 recommended — Monitoring Escalation ME-01
- Day 63 Patient accepted — Started ME-01 in the companion
- Day 66 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 49.
Primary contributors, last 14 days
- GI instability-6
- Treatment adherence+5
- Inflammatory activity-4
- Toxicity-4
What helped?
- Monitoring Escalation ME-01Day 62Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04
92%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 83% showed improvement
- median effect visible after 8 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 74 and rising
- WearableSleep 5.4 h, below personal baseline
- Inflammatory signalling ↓85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 70
- WearableHRV 38 ms, trending down
- Autonomic recovery ↑65
- WearableResting HR 80 bpm
- Wearable2,676 steps/day
- WearableShort sleep window
- Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 35/100
- Daily logFibre intake low in recent food logs
- Drug metabolism and exposure ↑20
- BloodToxicity index 51
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 2.9 · butyrate capacity 35/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 29 ms
- Sleep
- 5.4 h
- Steps
- 2,713
- Resting HR
- 80 bpm
Daily log: GI score 74, nutritional resilience 25, adherence 44.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01728 | 51% | S14 | SC-12 | improved | 41 |
| P-01897 | 51% | S14 | ME-01 | improved | 43 |
| P-01615 | 50% | S14 | ME-01 | improved | 48 |
| P-01531 | 48% | S14 | ME-01 | improved | 51 |
| P-01612 | 47% | S14 | ME-01 | improved | 51 |
| P-01656 | 47% | S14 | ME-01 | improved | 41 |
| P-01605 | 45% | S14 | ME-01 | improved | 41 |
| P-01810 | 45% | S05 | NP-02 | improved | 43 |
| P-01564 | 44% | S14 | ME-01 | improved | 39 |
| P-01720 | 44% | S14 | NP-02 | improved | 47 |
| P-01801 | 44% | S14 | SC-12 | improved | 42 |
| P-01808 | 44% | S10 | ME-01 | improved | 36 |